Candriam S.C.A. Sells 46,752 Shares of Mirum Pharmaceuticals, Inc. $MIRM

Key Points

• Candriam S.C.A. reduced its stake in Mirum Pharmaceuticals by 10.9%, now holding 382,979 shares valued at approximately $17.25 million.
• CEO Christopher Peetz sold 40,000 shares of the company's stock for $2.48 million, significantly reducing his position by 22.39%.
• Mirum Pharmaceuticals reported a 64.1% increase in revenue year-over-year, with $127.79 million in the last quarter, beating analyst estimates.

Candriam S.C.A. lowered its position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) by 10.9% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 382,979 shares of the company's stock after selling 46,752 shares during the quarter. Candriam S.C.A. owned approximately 0.77% of Mirum Pharmaceuticals worth $17,253,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in Mirum Pharmaceuticals by 4.8% in the first quarter. Vanguard Group Inc. now owns 2,540,061 shares of the company's stock valued at $114,430,000 after acquiring an additional 115,327 shares during the last quarter. GAMMA Investing LLC lifted its stake in Mirum Pharmaceuticals by 4,555.0% in the first quarter. GAMMA Investing LLC now owns 5,586 shares of the company's stock valued at $252,000 after acquiring an additional 5,466 shares during the last quarter. SG Americas Securities LLC lifted its stake in Mirum Pharmaceuticals by 174.9% in the first quarter. SG Americas Securities LLC now owns 19,182 shares of the company's stock valued at $864,000 after acquiring an additional 12,204 shares during the last quarter. Wealth Enhancement Advisory Services LLC lifted its stake in Mirum Pharmaceuticals by 2.1% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 16,685 shares of the company's stock valued at $752,000 after acquiring an additional 339 shares during the last quarter. Finally, MPM Bioimpact LLC lifted its stake in Mirum Pharmaceuticals by 19.7% in the fourth quarter. MPM Bioimpact LLC now owns 589,579 shares of the company's stock valued at $24,379,000 after acquiring an additional 96,856 shares during the last quarter.

Mirum Pharmaceuticals Stock Performance

NASDAQ:MIRM traded up $0.98 during mid-day trading on Tuesday, reaching $72.79. 286,911 shares of the company's stock were exchanged, compared to its average volume of 507,268. Mirum Pharmaceuticals, Inc. has a one year low of $36.86 and a one year high of $72.73. The firm has a market capitalization of $3.66 billion, a PE ratio of -60.02 and a beta of 0.94. The business's fifty day simple moving average is $55.24 and its two-hundred day simple moving average is $48.54. The company has a debt-to-equity ratio of 1.21, a quick ratio of 2.97 and a current ratio of 3.13.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The company reported ($0.12) EPS for the quarter, topping analysts' consensus estimates of ($0.31) by $0.19. Mirum Pharmaceuticals had a negative net margin of 13.65% and a negative return on equity of 24.76%. The business had revenue of $127.79 million for the quarter, compared to analyst estimates of $107.91 million. During the same period last year, the firm earned ($0.52) earnings per share. Mirum Pharmaceuticals's revenue for the quarter was up 64.1% compared to the same quarter last year. Analysts anticipate that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Insider Transactions at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, CEO Christopher Peetz sold 40,000 shares of the firm's stock in a transaction dated Monday, August 11th. The shares were sold at an average price of $62.00, for a total value of $2,480,000.00. Following the transaction, the chief executive officer directly owned 138,641 shares of the company's stock, valued at $8,595,742. This trade represents a 22.39% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Jolanda Howe sold 10,000 shares of the firm's stock in a transaction dated Thursday, August 7th. The shares were sold at an average price of $58.00, for a total transaction of $580,000.00. Following the completion of the transaction, the senior vice president directly owned 2,426 shares in the company, valued at approximately $140,708. This represents a 80.48% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 91,041 shares of company stock worth $5,320,624. 14.36% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on MIRM shares. Stifel Nicolaus set a $89.00 price objective on shares of Mirum Pharmaceuticals and gave the company a "buy" rating in a research report on Monday, August 11th. JMP Securities set a $81.00 price objective on shares of Mirum Pharmaceuticals and gave the company a "market outperform" rating in a research report on Thursday, August 7th. Wall Street Zen lowered shares of Mirum Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Monday. Raymond James Financial reissued a "strong-buy" rating on shares of Mirum Pharmaceuticals in a research report on Thursday, August 7th. Finally, Evercore ISI increased their price objective on shares of Mirum Pharmaceuticals from $77.00 to $89.00 and gave the company an "outperform" rating in a research report on Friday, August 8th. One equities research analyst has rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $74.13.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.